Last reviewed · How we verify
PQP
PQP is a quinolone-based antimalarial that inhibits parasite DNA gyrase and topoisomerase II, disrupting DNA replication in Plasmodium species.
PQP is a quinolone-based antimalarial that inhibits parasite DNA gyrase and topoisomerase II, disrupting DNA replication in Plasmodium species. Used for Malaria (treatment and prevention).
At a glance
| Generic name | PQP |
|---|---|
| Also known as | PQP 960 mg tablets |
| Sponsor | Medicines for Malaria Venture |
| Drug class | Quinolone antimalarial |
| Target | Plasmodium DNA gyrase and topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
PQP belongs to the 4-aminoquinoline class of antimalarials and works by intercalating into parasite DNA and inhibiting essential enzymes required for DNA synthesis and repair. This mechanism is effective against multiple Plasmodium species and helps prevent both clinical malaria and transmission.
Approved indications
- Malaria prevention and treatment (Plasmodium falciparum and other species)
Common side effects
- Gastrointestinal disturbance
- Headache
- Pruritus
- Visual disturbances
Key clinical trials
- A Healthy Volunteer Safety Study of Pyronaridine Tetraphosphate Taken in Combination With Piperaquine Tetraphosphate (PHASE1)
- Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP (PHASE1)
- DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil (PHASE3)
- Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania (PHASE2)
- Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria (PHASE3)
- Experimental Falciparum Transmission to Anopheles (PHASE1)
- Mass Drug Administrations of DHA-PQP to Accelerate Towards Malaria Elimination in Magude District, Southern Mozambique (NA)
- A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PQP CI brief — competitive landscape report
- PQP updates RSS · CI watch RSS
- Medicines for Malaria Venture portfolio CI